News & Events about Mind Medicine Mindmed Inc.
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the periods business highlights.
Numbers show:
read more...
MindMed Board has Presided over Botched Regulatory Strategies, Outsized Expenses, Soaring Executive Compensation, and Value Destructive Financings FCMs Four Highly Qualified Director Nominees to Bring Desperately Needed Accountability, Expertise, and Fresh Shareholder Focused Perspective to the ...
Meaningful Change is Needed at MindMed After Years of Poor Performance FCMs Candidates Have Decades of Relevant Industry Experience and are Laser Focused on Bringing MM-120 to Market FCM to Provide Detailed Operational Plan to Address MindMeds Operational Challenges SHERIDAN, Wyo., April 21, 2023 (...
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the Company or MindMed), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr. Felix Mueller, MindMed collaborators at University Hospital...
Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD Get Rating) have received a consensus rating of Buy from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among ...